(Q37998606)

26 August 2017

title

The future of inflammatory bowel disease management: combining progress in trial design with advances in targeted therapy (English)

1 reference

inflammatory bowel diseases

26 August 2017

main subject

0 references

2

Brian G Feagan

1 reference

26 August 2017

3

Paul Rutgeerts

1 reference

26 August 2017

Simon Travis

1

1 reference

26 August 2017

Sander van Deventer

series ordinal

4

1 reference

26 August 2017

publication date

1 February 2012

1 reference

Journal of Crohn's and Colitis

26 August 2017

published in

1 reference

26 August 2017

volume

6 Suppl 2

1 reference

26 August 2017

page(s)

S250-9

1 reference

The potential for disease modification in Crohn's disease

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Top-down therapy for IBD: rationale and requisite evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Conventional medical management of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Changing Crohn's disease management: need for new goals and indices to prevent disability and improve quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Implementing changes in clinical practice to improve the management of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Maintenance therapy with certolizumab pegol for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Infliximab for induction and maintenance therapy for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Certolizumab pegol for the treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Cluster randomised trials in the medical literature: two bibliometric surveys

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Orally administered L. lactis secreting an anti-TNF Nanobody demonstrate efficacy in chronic colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

The cholinergic anti-inflammatory pathway: towards innovative treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Induction of colonic regulatory T cells by indigenous Clostridium species

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Therapeutic targeting of Janus kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3.

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

A human gut microbial gene catalogue established by metagenomic sequencing

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1873-9946%2812%2960505-4

7 January 2021

10.1016/S1873-9946(12)60505-4

Identifiers

DOI

1 reference

26 August 2017

1 reference